Literature DB >> 19208594

Poor outcomes after acute myocardial infarction in systemic lupus erythematosus.

Mansi A Shah1, Amber M Shah, Eswar Krishnan.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE) is associated with higher risk for acute myocardial infarction (MI); but the post-infarction outcomes among these patients are unknown. Our objective was to compare post-acute MI outcomes in patients with SLE to those with diabetes mellitus (DM) and those with neither condition.
METHODS: We analyzed the risk for prolonged hospitalization and in-hospital mortality following acute MI in the 1993-2002 US Nationwide Inpatient Sample. We used logistic regression to calculate odds ratios (OR) for prolonged hospitalization and Cox proportional hazards regression to calculate hazard ratios (HR) for in-hospital mortality with and without adjustments for age, sex, race/ethnicity, socioeconomic status, and presence of congestive heart failure.
RESULTS: For the SLE (n = 2192), DM (n = 236,016), SLE/DM (n = 474), and control (n = 667,956) groups, the in-hospital mortality rates were 8.3%, 6.2%, 5.7%, and 4.7%, respectively. In multivariable regression models, all 3 disease groups had higher adverse outcome risk compared to control. The OR for prolonged hospitalization was higher for those with SLE (OR 1.48, 95% CI 1.32-1.79) compared to those with DM (OR 1.30, 95% CI 1.28-1.32). A similar pattern was observed for hazard ratios for in-hospital mortality as well (SLE, HR 1.65, 95% CI 1.33-2.04; DM, HR 1.11, 95% CI 1.07-1.14).
CONCLUSION: SLE, like DM, increases risk of poor outcomes after acute MI. These patients need to be triaged appropriately for aggressive care.

Entities:  

Mesh:

Year:  2009        PMID: 19208594     DOI: 10.3899/jrheum.080373

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus.

Authors:  Lisabeth V Scalzi; Christopher S Hollenbeak; Li Wang
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 3.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

Review 4.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

Review 5.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

Review 6.  Atherosclerosis in systemic lupus erythematosus.

Authors:  George Stojan; Michelle Petri
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

7.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

8.  Subclinical atherosclerosis and endothelial dysfunction in young South-Asian patients with systemic lupus erythematosus.

Authors:  Parasar Ghosh; Amresh Kumar; Sudeep Kumar; Amita Aggarwal; Nakul Sinha; Ramnath Misra
Journal:  Clin Rheumatol       Date:  2009-07-19       Impact factor: 2.980

9.  Presentation of systemic lupus erythematosus (SLE) in emergency department: a case report.

Authors:  Natália Fernandes; Guilherme Gomes; Carlos Capela
Journal:  BMC Res Notes       Date:  2013-05-05

10.  Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries.

Authors:  Ole Ahlehoff; Jesper Lindhardsen; Gunnar H Gislason; Jonas B Olesen; Mette Charlot; Lone Skov; Christian Torp-Pedersen; Peter R Hansen
Journal:  BMC Cardiovasc Disord       Date:  2012-09-24       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.